U.S. specialists and familiarity with biosimilars 2021
According to a survey conducted in 2021, 94 percent of oncologists indicated being very or somewhat familiar with biosimilars. The percentage of physicians who are "very familiar" with biosimilars was highest among diabetes specialists.